Skip to content

BIOSPECIFICS TECHNOLOGIES CORP: 10-K filed 2017-03-16

What BIOSPECIFICS TECHNOLOGIES CORP reported in its annual report filed 2017-03-16 (fiscal FY 2016): 30 published measures, 114 facts as tagged in accession 0001140361-17-012337.

This filing

Form
10-K (annual report)
Filed
2017-03-16
Fiscal period
fiscal FY 2016
Accession
0001140361-17-012337 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-3164,696,280USD
At 2015-12-3145,698,113USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-3156,281,943USD
At 2015-12-3144,810,209USD
At 2014-12-3130,256,855USD
At 2013-12-3122,332,439USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-314,763,364USD
At 2015-12-315,137,875USD
At 2014-12-319,810,816USD
At 2013-12-315,624,860USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-312,916,807USD92
2016-01-01 to 2016-12-3111,372,239USD366
2016-07-01 to 2016-09-303,053,593USD92
2016-04-01 to 2016-06-302,572,715USD91
2016-01-01 to 2016-03-312,829,124USD91
2015-10-01 to 2015-12-312,658,549USD92
2015-01-01 to 2015-12-319,617,632USD365
2015-07-01 to 2015-09-302,870,979USD92
2015-04-01 to 2015-06-301,757,204USD91
2015-01-01 to 2015-03-312,330,900USD90
2014-01-01 to 2014-12-314,645,960USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-3130,610,849USD
At 2015-12-3119,238,610USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2016-01-01 to 2016-12-317,061,404shares366
2015-01-01 to 2015-12-316,827,355shares365
2014-01-01 to 2014-12-316,477,457shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2016-01-01 to 2016-12-317,283,262shares366
2015-01-01 to 2015-12-317,272,989shares365
2014-01-01 to 2014-12-317,079,570shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2016-10-01 to 2016-12-310.41USD/shares92
2016-01-01 to 2016-12-311.61USD/shares366
2016-07-01 to 2016-09-300.43USD/shares92
2016-04-01 to 2016-06-300.37USD/shares91
2016-01-01 to 2016-03-310.4USD/shares91
2015-10-01 to 2015-12-310.38USD/shares92
2015-01-01 to 2015-12-311.41USD/shares365
2015-07-01 to 2015-09-300.42USD/shares92
2015-04-01 to 2015-06-300.26USD/shares91
2015-01-01 to 2015-03-310.35USD/shares90
2014-01-01 to 2014-12-310.72USD/shares365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2016-10-01 to 2016-12-310.4USD/shares92
2016-01-01 to 2016-12-311.56USD/shares366
2016-07-01 to 2016-09-300.42USD/shares92
2016-04-01 to 2016-06-300.35USD/shares91
2016-01-01 to 2016-03-310.39USD/shares91
2015-10-01 to 2015-12-310.36USD/shares92
2015-01-01 to 2015-12-311.32USD/shares365
2015-07-01 to 2015-09-300.39USD/shares92
2015-04-01 to 2015-06-300.24USD/shares91
2015-01-01 to 2015-03-310.32USD/shares90
2014-01-01 to 2014-12-310.66USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-01-01 to 2016-12-316,002,765USD366
2015-01-01 to 2015-12-314,933,328USD365
2014-01-01 to 2014-12-312,386,707USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-12-31133,904USD366
2015-01-01 to 2015-12-31105,782USD365
2014-01-01 to 2014-12-3121,416USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-314,311,777USD92
2016-01-01 to 2016-12-3117,026,416USD366
2016-07-01 to 2016-09-304,725,885USD92
2016-04-01 to 2016-06-303,833,596USD91
2016-01-01 to 2016-03-314,155,158USD91
2015-10-01 to 2015-12-313,894,516USD92
2015-01-01 to 2015-12-3114,443,315USD365
2015-07-01 to 2015-09-304,321,958USD92
2015-04-01 to 2015-06-302,662,974USD91
2015-01-01 to 2015-03-313,563,867USD90
2014-01-01 to 2014-12-316,966,927USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-3155,399,967USD
At 2015-12-3138,351,971USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-311,996,635USD
At 2015-12-31838,525USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2016-12-313,810,792USD
At 2015-12-312,547,920USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2016-01-01 to 2016-12-311,048,592USD366
2015-01-01 to 2015-12-311,802,466USD365
2014-01-01 to 2014-12-31829,613USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-01-01 to 2016-12-311,327,923USD366
2015-01-01 to 2015-12-311,034,288USD365
2014-01-01 to 2014-12-311,263,512USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-12-317,156,281shares
At 2015-12-316,918,579shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-12-3132,945,240USD
At 2015-12-3131,797,418USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2016-12-31258,355USD
At 2015-12-31275,206USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-12-31624,345USD
At 2015-12-31383,810USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2016-12-313,290,122USD
At 2015-12-31622,972USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-01-01 to 2016-12-3117,375,004USD366
2015-01-01 to 2015-12-3114,550,960USD365
2014-01-01 to 2014-12-317,032,667USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-12-317,896,616USD366
2015-01-01 to 2015-12-317,272,532USD365
2014-01-01 to 2014-12-315,814,185USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-01-01 to 2016-12-311,691,539USD366
2015-01-01 to 2015-12-31933,009USD365
2014-01-01 to 2014-12-31247,097USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2016-01-01 to 2016-12-3152,805USD366
2015-01-01 to 2015-12-3114,719USD365
2014-01-01 to 2014-12-3133,582USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-01-01 to 2016-12-31348,588USD366
2015-01-01 to 2015-12-31107,645USD365
2014-01-01 to 2014-12-3165,740USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2016-01-01 to 2016-12-318,669,915USD366
2015-01-01 to 2015-12-314,477,529USD365
2014-01-01 to 2014-12-311,957,702USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-2,667,150USD366
2015-01-01 to 2015-12-31455,799USD365
2014-01-01 to 2014-12-31429,005USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-12-311,262,872USD366
2015-01-01 to 2015-12-31-390,811USD365
2014-01-01 to 2014-12-31-2,051,335USD365

Inspect the source

Entity
BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
Captured
SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))